Jupiter Wellness

Jupiter Wellness, Inc. engages in the development of cannabidiol based medical therapeutics and wellness products. Its product line includes CaniSun, CaniSkin, and CaniDermRx. It operates through the following segments: sales and development of cannabidiol (CBD) based skin care and therapeutic products and sales of merchandise sold to theme parks segments.The company was founded by Brian S. John on October 24, 2018 and is headquartered in Jupiter, FL.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Safety Shot, Inc. engages in the business of developing cannabidiol (CBD) based medical therapeutics and wellness products. It operates under the Sales and Development of CBD Based Skin Care and Therapeutic Products, and Sales and Merchandise Sold to Theme Parks segments. The company was founded by Brian S. John on October 24, 2018 and is headquartered in Jupiter, FL.

Next Frontier Pharmaceuticals' Subsidiary Benuvia Signs Agreement with Global Wellness' Shanti Therapeutics Benuvia has begun focusing on Psilocybin, DMT, and MDMA. Benuvia's 83,000 square foot synthetic compound manufacturing facility is permitted by the U.S. DEA for Schedule I to III controlled substances, and is FDA registered.

Jupiter Wellness' Merger Partner Next Frontier Pharmaceuticals, Inc. Enters Psychedelic Drug Development and API Market

NEW ORLEANS, Jan. 4, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

JUPITER WELLNESS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Jupiter Wellness, Inc. - JUPW

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Jupiter Wellness, Inc. ("Jupiter" or the "Company") (NASDAQ: JUPW), in connection with the proposed merger of the Company with Next Frontier Pharmaceuticals, Inc. ("Next Frontier Pharmaceuticals").  Under the terms of the merger agreement, Next Frontier Pharmaceuticals' stockholders will be entitled to receive convertible stock of Jupiter Wellness that is convertible into 65,000,000, shares of Jupiter Wellness common stock at the closing of the transaction.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Jupiter Wellness, Inc.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Jupiter Wellness, Inc. (NASDAQ: JUPW) and Next Frontier Pharmaceuticals, Inc. is fair to Jupiter shareholders. Under the terms of the transaction, Next Frontier shareholders will receive shares of Jupiter convertible preferred stock that will be convertible into the common stock of Jupiter and no cash. Halper Sadeh encourages Jupiter shareholders to click here to learn more abo

Jupiter (JUPW) Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Jupiter Wellness, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – JUPW

Agrify

Flora Growth Corp

GrowGeneration Corp

High Tide

India Globalization Capital

Chicago Atlantic Real Estate Finance

Tilray Brands

The Valens Co

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

9 Hottest Stories from the Cannabis Sector This Week

Jupiter Wellness, Inc. (NASDAQ:JUPW) announced Thursday that it is acquiring Next Frontier Pharmaceuticals, Inc., through a merger with a subsidiary of Jupiter Wellness. Deal Details Under the terms of the agreement, Next Frontier Pharmaceuticals' stockholders will receive convertible stock of Jupiter Wellness – convertible into 65 million shares of Jupiter Wellness common stock and no cash at the closing of the transaction.

Jupiter Wellness & Next Frontier Pharmaceuticals Merge, Will Expand Cannabinoid & Psychedelics Drug Development

Owner of SYNDROS®(dronabinol), the only US-based FDA approved CII Tetrahydrocannabinol (THC), a liquid cannabinoid used in adults to treat: Chemotherapy Induced Nausea and Vomiting (CINV) associated in adult patients who have failed to respond adequately to conventional antiemetic treatments; and Anorexia associated with weight loss in adult patients with Acquired Immune Deficiency Syndrome (AIDS) 83,000 square foot manufacturing facility in Texas is FDA registered and licensed by the U.S. DEA to manufacture Schedule I to III controlled substances in a cGMP facility, with a DEA-exemption permit to export globally Five FDA-registered Investigational New Drugs Seminal patents in organic and synthetic cannabinoids Pending license approval to manufacture psychedelic pharmaceuticals JUPITER, FL and ROUND ROCK, TX / ACCESSWIRE / December 9, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), announced today it has signed a definitive agreement to acquire Next Frontier Pharmaceuticals, Inc. ("Next Frontier Pharmaceuticals"), through a merger with a subsidiary of Jupiter Wellness. Under the terms of the transaction, Next Frontier Pharmaceuticals' stockholders will receive shares of Jupiter Wellness convertible preferred stock that will be convertible into the common stock of Jupiter Wellness and no cash.

Jupiter Wellness Signs Definitive Agreement to Merge with Next Frontier Pharmaceuticals, a Leading Drug Developer and Manufacturer of Synthetic Cannabinoid Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / December 6, 2021 / Jupiter Wellness Acquisition Corp. (the "Company") announced today that it priced its upsized initial public offering of 12,000,000 units at $10.00 per unit. The units are expected to be listed on The Nasdaq Global Market ("Nasdaq") and trade under the ticker symbol "JWACU" beginning December 7, 2021.

Jupiter Wellness Acquisition Corp. Announces Pricing of Upsized $120 Million Initial Public Offering

JW-300 Demonstrates Efficacy in Treatment of Developing Burns (sunburn) in a Double-Blinded Placebo Controlled Clinical Trial. JUPITER, FL / ACCESSWIRE / November 16, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a wellness company specializing in the clinical development of skin therapeutics announced the results of a double-blinded placebo controlled trial of JW-300 for the treatment of first degree burns.

Jupiter Wellness Announces JW-300 Clinical Trial Results

JUPITER, FL / ACCESSWIRE / November 11, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a clinical stage company developing cannabinoid receptor agonists for the treatment of eczema, actinic keratosis, burns, and herpes cold sores, announced that it has received an official written response from a Type B pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) for JW-100, a topical drug the treatment of eczema. The main purpose of the pre-IND meeting was to evaluate the drug development plan for JW-100.

Jupiter Wellness Completes Pre-IND meeting with the U.S. Food & Drug Administration for JW-100 in the Treatment of Eczema

AI in medicine is projected to grow 18X from 2018 through 2025 to $35 billion JUPITER, FL / ACCESSWIRE / November 3, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced that it has filed a registration statement with the Securities and Exchange Commission to sponsor Jupiter Wellness Acquisition Corp. ("JUPW"), a special-purpose acquisition company, or SPAC, dedicated to investing in artificial intelligence (AI) based therapeutics and diagnostics with an initial funding target of $100 million. JUPW has finalized the recruitment and on-boarding of its board of directors and aims to be listed on the Nasdaq Capital Markets.

Jupiter Wellness Sponsors Jupiter Wellness Acquisition Corp SPAC Targeting AI Medical Therapeutics and Diagnostics

JUPITER, FL / ACCESSWIRE / October 19, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a clinical stage company developing a cannabinoid receptor agonist for the treatment of first degree burns, announced the enrollment and dosing of the first patient in the study. The double-blinded placebo-controlled study will enroll 50 patients with newly diagnosed first degree burns of superficial partial thickness on 10% or less of the patient's total body surface area.

Jupiter Wellness Announces First Patient Dosing for Double-Blinded Placebo Controlled Trial of JW-300 for the Treatment of First Degree Burns

JUPITER, FL / ACCESSWIRE / October 7, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today provided an update on its advancing clinical programs and commercial progress. Commercial: Photocil™ to Launch in Q1 2022 Photocil™ ("Phototherapy in a bottle"), a patented topical Over-the-Counter drug for the treatment of psoriasis and vitiligo is expected to launch in Q1 2022.

Jupiter Wellness Provides Shareholder Update on Multiple Clinical & Commercial Milestones

Pro Golf Hall of Fame Legend Extends Endorsement of CaniSun Suncare Products JUPITER, FL / ACCESSWIRE / September 8, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a developer of enhanced skin care therapeutics, sunscreens and treatments focused on the endocannabinoid system, today announced a multi-year extension of its endorsement agreement with PGA Golf Legend Ernie Els. Els, known as “The Big Easy,” will help promote the Company's patent pending CaniSun Suncare Product Line for two additional years.

Jupiter Wellness Announces Multi-Year Extension of Endorsement Agreement with Pro Golfer Ernie Els

Following receipt of a Pre-Assignment number from the FDA Jupiter Wellness requests Pre-IND meeting JUPITER, FL / ACCESSWIRE / August 23, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a developer of enhanced skin care therapeutics and treatments focused on the endocannabinoid system today announced it has submitted a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (FDA) in support of its JW-100 drug development program the treatment of patients with mild to moderate Eczema . The benefits of holding a pre-IND meeting are to receive early FDA feedback on proposed preclinical and clinical study plans confirming strategy for IND submission.

Jupiter Wellness Submitted a Pre-IND Meeting Request with the US FDA for its Proposed Clinical Program of JW-100 as a Treatment for Mild to Moderate Eczema

Following positive results from the JW-100 investigator initiated trials for Eczema, Jupiter Wellness to commence US FDA program JUPITER, FL / ACCESSWIRE / August 16, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced it has requested an IND number from the US Federal Drug Administration in preparation for a pre-IND submission to review preclinical and clinical studies for the use of JW-100 in the treatment of patients with mild to moderate eczema. The preparation of the pre-IND briefing document has been co-ordinated by a team of scientific, clinical and regulatory experts at Applied Biology Inc., (Irvine, CA) in concert with pharmaceutical and manufacturing expertise at Jupiter Wellness Inc. Jupiter Wellness previously reported that in a double-blinded, placebo controlled clinical trial of 55 patients using JW-100 was shown to significantly reduce ISGA scores in 50% of adult patients suffering from eczema after two weeks of use.

Jupiter Wellness Applies for IND number from the US Food and Drug Administration

NEW YORK, NY / ACCESSWIRE / July 26, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $32.5 Million Follow-On Offering of Common Stock and Warrants for Jupiter Wellness, Inc. (NASDAQ:JUPW). About Jupiter Wellness, Inc. Jupiter Wellness, Inc. (NASDAQ:JUPW) is a leading developer of skin care therapeutics and treatments.

Aegis Capital Corp. acted as Sole Bookrunner on a $32.5 Million Follow-On Offering of Common Stock and Warrants for Jupiter Wellness, Inc. (NASDAQ:JUPW).

JUPITER, FL / ACCESSWIRE / July 26, 2021 / Jupiter Wellness, Inc. (the "Company") (NASDAQ:JUPW), today announced the closing of an underwritten public offering (the "Offering") of 11,066,258 shares (the "Company Offering Shares") of common stock, par value $0.001 per share ("Common Stock") to be issued by the Company, 540,884 shares (the "Selling Stockholder Shares") of Common Stock to be sold by certain selling stockholders (the "Selling Stockholders") of the Company and warrants (the "Company Warrants") to purchase up to 11,607,142 shares of Common Stock, at a price to the public of $2.79 per Company Offering Share/Selling Stockholder Share and $0.01 per Company Warrant. The Company Warrants will be exercisable immediately upon issuance with an exercise price of $2.79 per share and will expire on the fifth anniversary of the original issuance date.

Jupiter Wellness Closes $32.5 Million Underwritten Public Offering of Common Stock and Warrants

The stock price of Jupiter Wellness Inc (NASDAQ: JUPW) fell by over 20% pre-market. This is why it happened.

JUPW Stock Fell Over 20% Pre-Market: Why It Happened

JUPITER, FL / ACCESSWIRE / July 21, 2021 / Jupiter Wellness, Inc. (the "Company") (NASDAQ:JUPW), today announced the pricing of an underwritten public offering (the "Offering") of 11,066,258 shares (the "Company Offering Shares") of common stock, par value $0.001 per share ("Common Stock") to be issued by the Company, 540,884 shares (the "Selling Stockholder Shares") of Common Stock to be issued by certain selling stockholders (the "Selling Stockholders") of the Company and warrants (the "Company Warrants") to purchase up to 11,607,142 shares of Common Stock, at a price to the public of $2.79 per Company Offering Share/Selling Stockholder Share and $0.01 per Company Warrant. The Company Warrants will be exercisable immediately upon issuance with the exercise price of 2.79 per share and will expire on the fifth anniversary of the original issuance date.

Jupiter Wellness Prices $32.5 Million Underwritten Public Offering of Common Stock and Warrants

JUPITER, FL / ACCESSWIRE / July 19, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced a multi-year agreement with Rigour International LLC as the exclusive authorized distributor of Jupiter Wellness Products within the Mainland of China and non-exclusive distributor for Hong Kong, Korea and South East Asian markets. Under the terms of the agreement, Rigour International is granted the exclusive right to distribute, commercialize and sell Comfort Cream, Canisun Sunscreen Products, Radiant Relief, Fit CBD, Temple Tonic and other related topical skin care Jupiter Wellness brands in China.

Jupiter Wellness Announces Multi-Year Distribution Agreement with Rigour International for Expansion in Asia

JUPITER, FL / ACCESSWIRE / July 15, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced that Dr Andy Goren has been appointed to its Scientific Advisory Board. Dr. Andy Goren has more than twenty years of experience in clinical research, development, and commercialization of breakthrough therapeutics and diagnostics.

Jupiter Wellness Announces Appointment of Dr. Andy Goren to Scientific Advisory Board

JUPITER, FL / ACCESSWIRE / July 13, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced a head-to-head trial comparing JW-100 lotion with Eucrisa crisaborole ointment 2% for the treatment of patients with mild to moderate eczema (Atopic Dermatitis). Eucrisa is an FDA-approved topical non-steroidal lotion containing crisaborole approved for the treatment of mild to moderate eczema.

Jupiter Wellness Announces initiation of Head-to-Head Trial Comparing JW-100 and Eucrisa(R) for the Treatment of Mild-to-Moderate Eczema

The stock price of Jupiter Wellness, Inc. (NASDAQ:JUPW) increased by over 9% during intraday trading. This is why it happened.

Jupiter Wellness Stock Increases Over 9%: Why It Happened

*Photo-Therapy in a tub JUPITER, FL / ACCESSWIRE / July 9, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced they have entered into an exclusive agreement to license Photocil™, a novel patented topical cream that provides clinically-proven relief for Psoriasis, Vitiligo and Atopic Dermatitis. The Agrement signed with the Applied Biology ("AB") whereby Jupiter Wellness is the exclusive licensee for Photocil in the United States.

News for Jupiter Wellness Stock (JUPW)